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Mary Danoudis1,2,3*† and Robert Iansek1,2†Abstract
Background: The progressive deterioration of gait in Huntington’s disease (HD) leads to functional decline and loss
of function. To understand the underlying mechanisms responsible for the gait changes in HD, we examined the
automatic control of gait by measuring the relationship between stride length and cadence. The relationship is
strongly linked in healthy adults during automatic gait but disrupted in pathological gait disorders, such as
Parkinson’s disease (PD).
Methods: The stride length cadence relationship was compared between seventeen participants with HD, twenty
with PD and twenty one healthy older adults (HOA). Participants had their gait recorded at self-selected preferred,
very slow, slow, fast and very fast speeds. Linear regression analysis was used to determine the slope and intercept
of the relationship which were compared between groups. The adjustment of stride length and cadence when
changing gait speeds was measured and compared within and between groups.
Results: Linearity was strong in all but two participants with HD and one with PD. Slope did not differ between
groups (p > 0.05) but intercept was lower in the HD and PD groups compared to HOA (p < 0.05). Stride length was
shorter in the HD and PD groups compared to controls at preferred and most adjusted speed conditions (p < 0.05) but
cadence did not differ between groups (p > 0.05) regardless of speed. The HD group adjusted stride length and cadence
similar to HOA when changing speed. The range of cadence across speed conditions did not differ between groups.
Conclusion: Scaling of stride length but not the regulation of cadence was found to be disrupted in participants
with HD.
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Huntington’s disease (HD) is an autosomal dominant
inherited neurodegenerative disorder that presents with
characteristic gait changes, including decreased walking
speed, step initiation difficulties [1-3] and a variable step-
ping pattern [4-6]. As the disorder progresses mobility
worsens, falls risk increases, functional capacity reduces
and the need for care increases [7]. There are few studies
to support rehabilitation of gait dysfunction in HD [8]
partly due to the limited understanding of the underlying
mechanisms responsible for the gait changes.* Correspondence: mary.danoudis@monashhealth.org
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article, unless otherwise stated.Gait impairments common to HD and PD include hypo-
kinesia and increased gait variability [1,2,9-12]. Disruption
to the regulation of step length, greater step to step vari-
ability and disturbed gait initiation have been reported to
occur before clinical signs of HD appear [2,13] and worsen
as disease severity progresses [2,10,13]. Cadence regulation
was found to be disrupted in the more advanced stages of
HD [2] but remained intact in PD [14]. Variability of angu-
lar kinematic gait parameters was shown to be higher in
HD and PD compared to controls [9] with chorea possibly
contributing to this variability in HD.
The relationship between stride length and cadence
(SLCrel) has been used to investigate central gait control
mechanisms in healthy adults, pathological gait and
lower limb prosthesis users [15-19]. Stride length and
cadence are the key determinants of gait speed [17,20].
When healthy adults increase or decrease their self-Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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stride length and cadence in a relatively constant linear
relationship [15,17,21]. Once gait speed is set then the
relationship between stride length and cadence (SLCrel)
functions to maintain it [15,17]. The SLCrel allows
for the regulation of gait when minimal attention is
required [15,16].
Motor dysfunction in Huntington disease is associated
with neuronal loss in the basal ganglia, involving the
caudate and putamen nuclei of the striatum and, in
more advanced disease, the subthalamic nucleus [22].
Neural networks involving these nuclei are important in
the preparation and the execution and maintenance of
movement and in executing well learned motor tasks
when they shift to being automatic, such as when walk-
ing without attention [23]. Disruption to their function
results in bradykinesia and akinesia, typical motor deficits
seen in HD [22]. The cortical motor areas play a key role
in the selection of stride length and the basal ganglia net-
works are critical in maintaining the selected stride length
[24]. Cadence, on the other hand, is thought to be con-
trolled via brainstem connections [24].
The SLCrel has been used to investigate the gait
changes in Parkinson’s disease (PD), which also involves
dysfunction of the basal ganglia [16]. Parkinson’s disease,
like HD, results in a slower gait with shortened steps and
normal cadence compared to healthy subjects [25,26]. The
slower gait in PD was shown to be due to disruption to the
regulation of step length, with cadence control remaining
unaffected [16,25,26]. Comparing the SLCrel of these two
basal ganglia disorders and comparing them to controls
may provide further insights into the functioning of the
automatic gait control mechanisms in HD.
This study aimed to investigate the SLCrel in HD. Spe-
cifically we aimed to compare the slope and intercept of
the SLCrel of participants with HD to that of partici-
pants with Parkinson’s disease and healthy controls dur-
ing self-selected speed walking trials. We proposed the
SLCrel would be altered in HD compared to controls
and that changes in the relationship would be the same
in HD to that found in PD.
Methods
Participants
Seventeen people with a diagnosis of HD, based on family
history and neurological examination by a neurologist spe-
cialized in the disorder, were recruited from a Huntington’s
disease data base and from local support groups. Twenty
participants with PD were recruited from a Movement
Disorders clinic and 21 health older adults (HOA) were
recruited from community groups. Inclusion criteria for
all participants included the ability to provide informed
written consent (a score of ≥24 on the Mini Mental State
Examination score, MMSE), being able to walk unassistedover 12 metres and being able to follow instructions. Par-
ticipants were excluded if they had any other medical con-
dition that interfered with their walking. Ethics approval
was obtained from the Southern Health Research Ethics
Committee and the Tasmanian Statewide and Mental
Health Services Research Committee. All participants pro-
vided written informed consent prior to testing.
Gait assessment
Participants were tested at one of two locations, Melbourne
or at the Hobart Menzies Research Institute, Australia. Gait
measurements were recorded by a computerized walk-
way system, the GAITRite® (CIR Systems Inc., USA).
The GAITRite® is valid and reliable in measuring gait in
people with HD [27], PD [28] and HOA [29]. The elec-
tronic walkway used in Melbourne was 8 metres long
and that at the Menzies Research Institute 4.6 metres
long. To have comparable number of steps recorded by
the two systems, gait data was collected over three trials
on the longer mat and over five trials on the shorter one
for all speed conditions. Gait speed, stride length and
cadence were collected at five speeds; preferred, very
slow, slow, fast and very fast. The first walking trial for
each speed condition was considered to be practice and
not used in the analysis. Participants walked at pre-
ferred speed first to avoid any influence from the other
speed conditions. The remaining walking conditions
were counterbalanced to ensure fatigue did not influ-
ence the results. Participants commenced walking 2 me-
tres before the start of the mat and finished 2 metres
past the end of the mat to avoid acceleration and slow-
ing down during data capture. Participants self-selected
their walking speeds in order to minimize attention and
maintain ‘automatic’ walking. Standardized instructions,
given to each participant prior to the commencement of
each walking trial, were to walk at normal/preferred pace
and to walk slow, very slow, fast or very fast compared to
normal/preferred walking pace. Participants with PD were
tested after taking their usual dose of PD medications.
The primary gait variables analyzed were stride length
and cadence, with stride length normalized to leg length
(mean stride length divided by leg length). The SLCrel
was plotted for each participant and was expressed as
slope (ratio stride length to cadence as speed changes)
and intercept, with data from all speed conditions being
used. We reported the intercept at a cadence of 100 steps/
min to ensure intercept values were within the data range
of all participants [15]. This provided a more valid com-
parison of the intercept between groups compared to
using an intercept of zero cadence. When calculating
intercept and slope, cadence was set as cadence-100. A
linear model R2 value of 0.80 was set as the minimum
value for accepting the relationship as linear for SLCrel
plots. Based on our previous work, if very fast trials had
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were removed and R2 values reviewed [15].
Secondary measures investigated the effect of changing
speed on normalized stride length (nSL) and cadence
and included: calculation of the minimum, maximum
and range for nSL and cadence for each group; deter-
mination of the changes to mean nSL and cadence in
the four adjusted speed conditions compared to the pre-
ferred condition for each group; and mean values for
normalized gait speed, nSL and cadence for all speed
conditions compared between groups. Confounders, age
and disease duration (for HD and PD groups), were se-
lected as they have been shown to influence gait [30-33].
The effect of psychotropic medications on the SLCrel in
the HD group was also investigated.
Clinical assessment
Participants were characterized according to age, gender,
height, leg length, body mass index, MMSE scores and
disease duration and severity (HD and PD groups). Psy-
chotropic medications were recorded for the HD group.
Disease severity for the HD group was measured using
the Unified Huntington’s Disease Rating Scale (UHDRS),
motor subscale [34]. The UHDRS has a maximum score
of 124, with a higher score indicating greater impairment
[34]. Disability was quantified using the Total Functional
Capacity (TFC) scale and the Independence Scale [34]
[35]. The TFC scale has a maximum score of 13, indicat-
ing maximum functional capacity, and is divided into 5
stages; stage 1 indicating early stage and stage 5 indicating
late stage [35]. The Independence Scale is scaled in levels
from 10 (total bed care) to 100 (asymptomatic). Disease
severity for the PD group was rated using the Unified
Parkinson’s Disease Rating Scale (UPDRS) motor, max-
imum score of 56 [36], and the 5 stage Hoehn and Yahr
(H&Y) staging tool, with stage 1 indicating mild disease
and stage 5 indicating severe disease [37].
Statistical analysis
Linear regression analysis was used to determine slope,
intercept and R2 for each participant. One way between
groups ANOVA was used to compare group means with
Bonferroni post-hoc analyzes. Adjustment was made for
age when comparing gait measures, slope, intercept, mini-
mum, maximum and range of nSL and cadence values. Ad-
justment was also made for disease duration when
comparing the SLCrel of HD and PD groups. Pearson cor-
relation was computed to analyze relationships between
slope and intercept with disease severity for HD and PD
groups. Differences in gait speed, stride length and cadence
within groups across 5 speed conditions were examined
using one way repeated measure ANOVA. Independent-
samples-t-test was used to compare intercept, slope, and R2
in the preferred speed condition for HD participants onor off psychotropic medications. Data was analyzed
using SPSS® (v20). Level for statistical significance was
set at p ≤ 0.05 [38].
Results
Characteristics
Participants in the HD group were younger than PD (p =
0.005) and HOA (p < 0.001) participants (Table 1). MMSE
scores were lower in HD (p = 0.03) and PD (p = 0.03)
groups compared to controls. Data for CAG repeats, avail-
able for 15 participants with HD, ranged from 40 to 51.
The mean (SD) total TFC score was 7.9 (3.5). More than
50% of participants were in the early stages of HD; five
were in mid and two in late stage. Activity limitation
scores for HD group showed 13 required no or minimal
assistance with finances and some domestic chores but
remained independent with personal care with the
remaining four participants living at home but needing as-
sistance with personal care and domestic tasks. Eleven of
the HD participants reported taking antipsychotic medica-
tions and 13 were prescribed antidepressants.
All but one participant in the PD group were taking
Parkinson’s medications. Time from when PD medications
were taken to when testing commenced ranged from
within 30 minutes up to 4.5 hours, average time being
1.9 hours. Dyskinesia was not present in the PD partici-
pants. Disease severity was mild, with 13 participants at
Hoehn and Yahr early stages 1–2 and five at mid stage 3.
Motor impairment was correspondingly mild with 14 hav-
ing a UPDRS motor score of 15/56 or less.
Gait measures
At preferred speed, HD and PD groups walked slower
compared to HOA (p <0.05) due to reduction of nSL (p <
0.05) (Table 2). After adjusting for age results for speed
and nSL were unchanged however cadence was lower in
the HD group compared to PD (p = 0.004) and HOA
groups (p < 0.001).
The HD group had shorter nSL compared to controls in
most adjusted speed conditions (Table 2). Cadence did not
differ between groups for all speed conditions (p > 0.05).
Adjusting for age resulted in nspeed being significantly
slower in the HD group compared to the PD and control
groups at very slow speed (p = 0.02, p = 0.003 respectively)
and slower than controls at slow gait speed (p = 0.015).
Adjusting for age did not change results for nSL however
cadence in the HD group was lower than controls in the
fast speed condition (p = 0.017) and lower in the PD group
compared to controls at very fast speed (p = 0.03).
Stride length cadence relationship - SLCrel
Inspection of the SLCrel plots in the HD group showed
nonlinear relationships for two participants, with R2 values
0.67 and <0.001 and no trials with a cadence >150 steps/
Table 1 Group characteristics
HD (n = 17) PD (n = 20) HOA (n = 21) p values between groups
Age, yrs 60.00 (10.5) 68.9 (8.8) 71.7 (4.0) <0.001
Male, n (%) 9 (53) 16 (80) 8 (38) -
Height, cm 170.8 (7.2) 171.5 (8.5) 166.6 (6.2) 0.083
Leg length, cm 87.3 (4.7) 89.4 (5.9) 85.6 (3.7) 0.060
BMI 26.9 (7.2) 26.3 (2.4) 24.9 (3.2) 0.362
MMSE 27.4 (2.2) 27.5 (1.9) 29.0 (1.4) 0.011
Disease duration, yrs 7.25 (4.3) 5.6 (5.5) - 0.430
Disease severity1 25.8 (10.63) 13.6 (6.24) - n/a
Disease stage2 2 (IQR 1,3) 2 (IQR 1,3) - n/a
Note. Means and SD unless stated otherwise; HD Huntington’s disease, PD Parkinson’s disease, HOA healthy older adults; BMI body mass index, MMSE Mini Mental
State Examination, IQR inter quartile range; Disease severity, 1Unified Huntington’s Disease Rating Scale total motor score for HD group and Unified Parkinson’s Disease
Rating Scale total motor score part III for the PD group; Disease stage, 2Stage of disease based on Total Functional Capacity scores for HD group, Hoehn & Yahr for PD
group; n/a, not applicable.
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intercept analysis. All other relationships were positive
and linear with R2 values ≥ 0.82. One participant in the
PD group, excluded from the SLCrel analysis, had a R2
value of 0.39. The remaining PD participants had R2
values ≥0.85. One control participant had a R2 value 0.66,
which, after removal of trials with cadences >150 steps/
min, was R2 = 0.9. All remaining HOA participants had
R2 ≥ 0.82.
Intercept and slope
Figure 1 shows nSL plotted against cadence including all
data points for all participants and mean regression lines
for each group. The HD and PD groups had lower inter-
cepts compared to the HOA group (p≤0.05) but slopeTable 2 Gait parameters for adjusted speed conditions compa
Parameter HD v HOA HD v P
nspeed very slow 0.68 (0.34) v 0.86 (0.22) p = 0.11 0.68 (0.3
nspeed slow 1.01 (0.36) v 1.16 (0.20) p = 0.17 1.00 (0.3
Nspeed preferred 1.30 (0.35) v 1.52 (0.17) p = 0.02 1.31 (0.3
nspeed fast 1.65 (0.42) v 1.86 (0.18) p = 0.08 1.65 (0.4
nspeed very fast 2.07 (0.44) v 2.29 (2.32) p = 0.12 2.07 (0.4
nSL very slow 1.00 (0.33) v 1.29 (0.15) p = 0.001 1.00 (0.3
nSL slow 1.25 (0.30) v 1.46 (0.12) p = 0.01 1.25 (0.3
nSL pref 1.44 (0.28) v 1.63 (0.10) p = 0.02 1.44 (0.2
nSL fast 1.60 (0.26) v 1.78 (0.12) p = 0.02 1.60 (0.2
nSL very fast 1.74 (0.25) v 1.91 (0.18) p = 0.08 1.74 (0.2
Cadence very slow 78.89 (17.47) v 79.14 (14.0) p = 1.0 78.89 (1
Cadence slow 94.64 (16.81) v 95.32 (10.92) p =1.0 94.64 (1
Cadence pref 106.1 (14.46) v 112.03 (9.17) p = 0.26 106.1 (1
Cadence fast 121.9 (17.58) v 124.8 (10.17) p =1.0 121.9 (1
Cadence very fast 141.7 (16.33) v 144.8 (12.69) p =1.0 141.7 (1
Note. Means and SD unless stated otherwise; HD Huntington’s disease, HOA health
nSL, normalized stride length.did not differ between groups (p = 0.26) (Table 3).
Adjusting for age did not change results for intercept,
(p = 0.009), or slope (p = 0.24). Intercept and slope did
not differ between the HD and PD groups (p=1.0,
p=0.43 respectively) and results did not change after
adjusting for disease duration (p = 0.88).
In the HD group, intercept correlated with disease se-
verity, UHDRS scores, r = −.81, p < .001; slope had a
medium but not significant relationship with disease se-
verity, r = .47, p = 0.08; and there was a significant correl-
ation between R2 and disease severity, r = −.52, p = 0.05.
Results were similar for the PD group, with intercept but
not slope or R2 correlating with disease severity, UPDRS
scores, r = −.67, p = 0.002, r = −.009, p = 0.97 r = -.39, p =
.095 respectively. Comparison between HD participantsred between groups
D PD v HOA
4) v 0.82 (0.22) p = 0.35 0.82 (0.22) v 0.86 (0.22) p = 1.0
6) v 1.09 (0.18) p = 0.95 1.09 (0.18) v 1.16 (0.20) p = 1.0
2) v 1.31 (0.21) p = 1.0 1.31 (0.21) v 1.52 (0.17) p = 0.02
2) v 1.53 (0.21) p = 0.69 1.53 (0.21) v 1.86 (0.18) p = 0.002
4) v 1.92 (0.28) p = 0.48 1.92 (0.28) v 2.29 (2.32) p = 0.001
3) v 1.15 (0.23) p = 0.19 1.15 (0.23) v 1.29 (0.15) p = 0.20
0) v 1.32 (0.18) p = 0.89 1.32 (0.18) v 1.46 (0.12) p = 0.09
8) v 1.43 (0.20) p = 1.0 1.43 (0.20) v 1.63 (0.10) p = 0.01
6) v 1.55 (0.20) p = 1.0 1.55 (0.20) v 1.78 (0.12) p = 0.001
5) v 1.69 (0.23) p = 1.0 1.69 (0.23) v 1.91 (0.18) p = 0.01
7.47) v 84.39 (11.73) p = 0.76 84.39 (11.73) v 79.14 (14.00) p = 0.75
6.81) v 99.47 (9.83) p = 0.75 99.47 (9.83) v 95.32 (10.92) p = 0.89
4.46) v 110.22 (6.96) p = 0.70 110.22 (6.96) v 112.03 (9.17) p = 1.0
7.58) v 118.9 (6.28) p = 1.0 118.9 (6.28) v 124.8 (10.17) p = 0.35
6.33) v 136.1 (11.76) p = 0.65 136.1 (11.76) v 144.8 (12.69) p = 0.14






























Figure 1 SLCrel for 3 groups, cadence set at cadence-100. NOTE SLCrel, stride length-cadence relationship.
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ence for intercept, slope or R2 values (p > 0.05).
Modulation of gait speed, stride length and cadence
Participants in the HD group did not differ to controls
or to the PD group for their mean minimum and max-
imum or range of cadence across speed conditions (p >
0.05) (Table 3). The HD group did however have a
smaller minimal nSL (p < 0.001) and shorter but not sig-
nificant maximum nSL (p = 0.20) compared to controls
(Table 3). The mean minimum nSL of the PD group did
not differ to the HD or control groups (p>0.05) however
their mean maximum nSL was shorter than controls (p =
0.01). There was a trend for the HD group’s range for nSL
to be greater than that of HOA (p = 0.06) but was greater
compared to the PD group (p = 0.009) (Table 3). Adjusting
for age did not change these results.
All groups decreased or increased their speed signifi-
cantly compared to their preferred speed (p < 0.05) with
a corresponding significant increase or decrease of nSL
and cadence for each speed condition compared to base-
line (p < 0.05) (Figure 2). The HD group adjusted their
nSL and cadence when walking slower or faster thanTable 3 SLCrel and minimum, maximum and range of nSL, ca
HD (n = 15) PD (n = 19)
Slope 0.013 (0.004) 0.011 (0.004)
Intercept 1.34 (0.208) 1.34 (0.210)
R2 0.90 (0.047) 0.94 (0.054)
Min nSl 0.940 (0.322) 1.124 (0.233)
Max nSL 1.791 (0.265) 1.721 (0.232)
Range nSl 0.853 (0.300) 0.597 (0.244)
Min cad 73.03 (14.09) 82.34 (11.67)
Max cad 140.87 (14.78) 137.08 (12.26)
Range cad 67.8 (20.27) 54.7 (15.62)
Note. Non adjusted results; Means and SD unless stated otherwise; HD Huntington’s
determination, Min nSL minimum normalized stride length, Max nSL maximum normtheir preferred speed similar to controls. For example
the percentage change of nSL in the adjusted speed condi-
tions compared to preferred nSL, HD versus controls was:
very slow speed −30.6% versus −20.9%; slow speed −13.2%
versus 10.4%; fast speed 11.1% versus 9.42%; and very fast
speed 20.8% versus 17.2%. The PD group also made simi-
lar adjustments to nSL and cadence compared to controls.
Discussion
This is the first study to investigate the SLCrel in HD. The
key finding was the lower intercept for the HD group com-
pared to controls. In other words, for any given cadence,
stride length was reduced in HD compared to controls,
consistent with a reduced scaling capacity. All except two
participants with HD and one participant with PD demon-
strated a strong linear relationship between stride length
and cadence. Participants with HD were able to modulate
their walking speed by adjusting both stride length and ca-
dence in the same proportion to the HOA and PD groups.
The HD group had a lower intercept of their SLCrel
compared to controls suggesting their stride length is
scaled lower regardless of gait speed. The PD group also
demonstrated a lower intercept, which has been previouslydence
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Figure 2 Comparison of mean normalized stride length (A) and cadence (B) values across 5 speed conditions for HD, PD and HOA
groups. All groups had significant change in nstride and cadence in four speed conditions compared to their preferred condition (p < 0.001).
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slope; the stride length cadence ratio for the HD and PD
groups did not differ to controls. The lower intercept
found in PD participants has been shown to increase to-
ward that of controls after taking levodopa [16]. Levodopa
improves stride length in PD by its action on the basal
ganglia. This suggests similar pathways in the basal ganglia
may be disrupted in both HD and PD and that gait speed
is reduced in both groups due to disruption to the regula-
tion of stride length by the basal ganglia. Intercept was
negatively associated with disease severity in both groups
which is consistent with step length shortening in both
HD and PD as these disorders progress [2,39].
Studies of healthy adults have demonstrated that the ra-
tio between stride length and cadence, as measured by
slope of the SLCrel plot, is consistent as speed changes ex-
cept possibly at higher speeds [15,17,40]. The consistency
of the SLCrel slope has also been demonstrated in PD and
Progressive Supranuclear palsy [16,18]. This current study
also showed the HD group, when adjusting their walking
speed, modulated stride length and cadence in a constant
ratio with slope not differing to that of the PD and control
groups. Walking at self-selected speed in a stable environ-
ment with minimal attention is controlled by the basal gan-
glia through its connections to frontal cortical regions [41].
We suggest that these neural connections are responsible
for maintaining the stable relationship between stride
length and cadence which in turn allows for the running of
self-selected speed in automatic mode. The findings also
suggest the central pathways responsible for this regulation
were intact in this sample. Slope was not associated with
disease severity however this result may be influenced by
the mild to moderate disease severity of participants in-
cluded in this sample. Future studies need to investigate the
SLCrel slope in participants with more severe disease.
People with HD were able increase or decrease their
walking speed by making similar adjustments to controls of
their stride length and cadence, which is agreement with
past studies [3-5]. We showed both stride length and ca-
dence increased as speed increased however past studies re-
ported variable contributions to changing gait speed [3,4].We also demonstrated that cadence did not differ between
HD and HOA groups across all speed conditions nor did
their minimum and maximum cadences and range of
change in cadence differ, which has not been previously
reported. These findings suggest timing of gait may be
intact in HD.
The use of strategies shown to normalize stride length
in PD [39] have not been investigated in HD. The diffi-
culty in synchronizing stepping to external cueing devices
in HD is reported to be due to attentional deficits [6] lim-
iting their clinical usefulness in gait rehabilitation for HD
with impaired cognition. In addition the use of a metro-
nome aims to increase gait speed by increasing cadence
and does not address disruption to step length regula-
tion. Future research is required to evaluate the effect-
iveness of specific interventions, in particular strategies to
increase step length using visual cues or attention [39], on
improving gait in HD.
There were limitations to this study. Most participants
in the HD and PD groups were in the early stages of the
disorders and may not be representative of those with
more severe disease. This sample of participants with HD
was heterogeneous however it was beyond the scope of
this study to recruit a larger sample because of the diffi-
culty in identifying people who met the inclusion criteria.
The resulting small numbers in each of the four stages of
the disorder meant comparison of gait and the SLCrel be-
tween the HD subgroups could not be done. The small
numbers also meant this study could not investigate
whether the SLCrel of HD participants who were predom-
inantly hypokinetic differed from those participants with
significant chorea. The inclusion of only two participants
in the HD group with marked disruption to the SLCrel
prevented any meaningful investigation of the relationship
between disrupted SLCrel and disease severity and disease
duration. Future studies need to investigate the SLCrel
across the HD stages with larger numbers to determine if
this relationship remains stable over the course of the dis-
order. The HD group also demonstrated a greater range of
nSL compared to the PD group and control group. The
basis for this finding is unclear but may reflect the
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in this current study. This is a possible topic for future re-
search. As measures of disease severity differed for the
HD and PD groups, it was not possible to determine if dis-
ease severity contributed to differences between them.
Levodopa has been shown to increase the intercept in PD
[16]. In this current study participants with PD were only
tested after taking levodopa. Future studies need to com-
pare the SLCrel of PD participants before levodopa medi-
cation with that of HD participants.
Conclusion
This study provides further insights into the mechanisms
contributing to the gait changes in HD. These results
will provide guidance to clinicians in the development of
effective interventions to improve mobility and function
in people with HD.
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